Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy

Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and few effective targeted therapy options. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been granted accelerated approval by FDA for patients with deleterious BRCA-mutated human epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xue, Hu, Nanlin, Cui, Lina, Si, Yiran, Yue, Jian, Zheng, Fangchao, Kang, Yikun, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906627/
https://www.ncbi.nlm.nih.gov/pubmed/35156571
http://dx.doi.org/10.2174/1568009622666220214092207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906627/
https://www.ncbi.nlm.nih.gov/pubmed/35156571
http://dx.doi.org/10.2174/1568009622666220214092207

Ejemplares similares